Last reviewed · How we verify

Iota-Carrageenan

NicOx · FDA-approved active Small molecule

Iota-carrageenan is a natural polysaccharide that forms a protective physical barrier on nasal mucosa to trap and prevent viral particles from infecting respiratory epithelial cells.

Iota-carrageenan is a natural polysaccharide that forms a protective physical barrier on nasal mucosa to trap and prevent viral particles from infecting respiratory epithelial cells. Used for Prevention and treatment of common cold caused by rhinoviruses and other respiratory viruses.

At a glance

Generic nameIota-Carrageenan
Also known asNCX-4240, Placebo
SponsorNicOx
Drug classAntiviral polysaccharide
ModalitySmall molecule
Therapeutic areaVirology / Respiratory Infection
PhaseFDA-approved

Mechanism of action

Iota-carrageenan, derived from red seaweed, works through a non-systemic topical mechanism by coating the nasal epithelium and creating a viscous barrier that mechanically traps respiratory viruses (particularly rhinoviruses and other enveloped viruses) before they can attach to and infect host cells. This physical blocking approach does not rely on receptor antagonism or enzymatic inhibition, making it a unique antiviral strategy with a low potential for resistance development.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: